472 related articles for article (PubMed ID: 25600565)
1. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.
Bellmunt J; Mullane SA; Werner L; Fay AP; Callea M; Leow JJ; Taplin ME; Choueiri TK; Hodi FS; Freeman GJ; Signoretti S
Ann Oncol; 2015 Apr; 26(4):812-817. PubMed ID: 25600565
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma.
Zhang B; Yu W; Feng X; Zhao Z; Fan Y; Meng Y; Hu S; Cui Y; He Q; Zhang H; Li D; He Z; Zhou L; Jin J; Han W
Med Oncol; 2017 May; 34(5):94. PubMed ID: 28409437
[TBL] [Abstract][Full Text] [Related]
3. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
[TBL] [Abstract][Full Text] [Related]
4. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
[TBL] [Abstract][Full Text] [Related]
5. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R
Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826
[TBL] [Abstract][Full Text] [Related]
6. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
[TBL] [Abstract][Full Text] [Related]
7. Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis.
Liu H; Ye T; Yang X; Lv P; Wu X; Zhou H; Lu H; Tang K; Ye Z
Dis Markers; 2020; 2020():8375348. PubMed ID: 32685057
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in malignant salivary gland tumors.
Harada K; Ferdous T; Ueyama Y
BMC Cancer; 2018 Feb; 18(1):156. PubMed ID: 29409471
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.
Wen Y; Chen Y; Duan X; Zhu W; Cai C; Deng T; Zeng G
Clin Exp Med; 2019 Nov; 19(4):407-416. PubMed ID: 31407099
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic value of PD-1/PD-L1 expression in upper tract urothelial carcinoma].
Campedel L; Seisen T; Cussenot O; Comperat E; Varinot J; Rouprêt M; Cancel-Tassin G
Prog Urol; 2018 Dec; 28(16):900-905. PubMed ID: 30219646
[TBL] [Abstract][Full Text] [Related]
11. Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research.
Necchi A; Lo Vullo S; Giannatempo P; Raggi D; Perrone F; Nicolai N; Catanzaro M; Biasoni D; Torelli T; Piva L; Stagni S; Salvioni R; Mariani L; Colecchia M
Clin Genitourin Cancer; 2018 Apr; 16(2):e403-e410. PubMed ID: 29111177
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
Amoils M; Kim J; Lee C; Sunwoo JB; Colevas AD; Aasi SZ; Hollmig ST; Ma Y; Divi V
Otolaryngol Head Neck Surg; 2019 Jan; 160(1):93-99. PubMed ID: 30012051
[TBL] [Abstract][Full Text] [Related]
13. Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.
Kamamoto D; Ohara K; Kitamura Y; Yoshida K; Kawakami Y; Sasaki H
J Neurooncol; 2018 Sep; 139(2):251-259. PubMed ID: 29675794
[TBL] [Abstract][Full Text] [Related]
14. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
[TBL] [Abstract][Full Text] [Related]
16. Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients.
Zhao YJ; Sun WP; Peng JH; Deng YX; Fang YJ; Huang J; Zhang HZ; Wan DS; Lin JZ; Pan ZZ
Cancer Manag Res; 2018; 10():1-11. PubMed ID: 29296096
[TBL] [Abstract][Full Text] [Related]
17. Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma.
Mullane SA; Werner L; Rosenberg J; Signoretti S; Callea M; Choueiri TK; Freeman GJ; Bellmunt J
Sci Rep; 2016 Jun; 6():27702. PubMed ID: 27283319
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.
Sonpavde G; Pond GR; Mullane S; Ramirez AA; Vogelzang NJ; Necchi A; Powles T; Bellmunt J
BJU Int; 2017 Apr; 119(4):579-584. PubMed ID: 27700015
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
